The ‘Ten Commandments’ for the 2022 European Society of Cardiology guidelines on cardio-oncology
Open Access
- 24 November 2022
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (1), 10-11
- https://doi.org/10.1093/eurheartj/ehac666
Abstract
The 2022 European Society of Cardiology (ESC) guidelines on cardio-oncology1 advise cardiologists, oncologists, and haematologists how to manage patients with cancer who may be at risk of cancer therapy-related cardiovascular toxicity (CTR-CVT).This publication has 3 references indexed in Scilit:
- 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)European Heart Journal, 2022
- Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statementEuropean Heart Journal, 2021
- Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio‐Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio‐Oncology SocietyEuropean Journal of Heart Failure, 2020